top of page

Technical Considerations for Experimental Design (Part I)

This session will cover the key components that should be considered when developing a MPS model, such as the context of use, and physical and biological inputs (including cells, matrices and media). Furthermore, the concept of good experimental design for MPS will be presented using a case study example.

Date & Time

Thursday, July 20, 2023 at 10:00 AM ET

Duration

90 minutes

Agenda

Welcome and Introduction

Jason Ekert, UCB Pharma

Rhiannon David, AstraZeneca


Considerations for MPS development: Cells

Jason Ekert, UCB Pharma


Considerations for MPS Development: Matrices, Scaffolds and Media

Rhiannon David, AstraZeneca


Experimental Design for MPS studies

Jonathan Cairns, AstraZeneca


Q&A


Session Slides:


IQ MPS PharmTox Training Module 1 Sesssion 2 - Technical Considerations for Experimental D
.pdf
Download PDF • 4.01MB

Moderators and Presenters

Jason Ekert

Head, US Discovery Translational Technology

UCB Pharma

<h2 class="font_2"><strong>Jason Ekert</strong></h2>
<p class="font_8">Head, US Discovery Translational Technology</p>
<p class="font_8">UCB Pharma</p>

Jason is responsible for the planning and directing of Complement biology and translational biology research, as well as seeking partnerships with research institutions and companies to remain on the leading edge of drug discovery. Before joining UCB he was Senior Director, GSK Fellow and Head of the Complex In Vitro Models (CIVM) group at GlaxoSmithKline. He was responsible for an integrated enterprise strategy for R&D applications of complex human-relevant and translatable complex in vitro models. He’s currently the past chair for the IQ-MPS affiliate and co-leads the regulatory sub-group for the IQ-MPS affiliate.

<h2 class="font_2"><strong>Jason Ekert</strong></h2>
<p class="font_8">Head, US Discovery Translational Technology</p>
<p class="font_8">UCB Pharma</p>

Rhiannon David

Director of Microphysiological Systems (Safety Assessment)

AstraZeneca

Rhiannon leads the development and integration of advanced cell models, including spheroids and MPS, to improve the human-translation of pre-clinical safety assessment. Prior to joining AZ, following completion of her PhD at the University of Birmingham, Rhiannon undertook postdoctoral research at Imperial College London where she developed an interest in novel techniques that would improve the in vivo relevance of in vitro assays. After joining AZ in 2015, Rhiannon led the development of a bone marrow MPS for improved pre-clinical safety assessment.

<h2 class="font_2"><strong>Jason Ekert</strong></h2>
<p class="font_8">Head, US Discovery Translational Technology</p>
<p class="font_8">UCB Pharma</p>

Jonathan Cairns 

Principal Biostatistician

AstraZeneca

Specialising in high-throughput methods and omics, Jonathan studied for a PhD at the Cancer Research UK Cambridge Institute, in multi-omic analysis of p53's Mode of Action. Subsequently, he completed a postdoc at the Babraham Institute, centering around the identification of long-range gene regulatory events through Capture Hi-C data. At AstraZeneca, in addition to his work on the experimental design and analysis of Bone Marrow Microphysiological System data, he leads the Experimental Design for ‘Omics initiative, with a particular interest in single-cell methods.

bottom of page